Genmab A/S
GMAB
$21.78
$0.110.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.89% | 30.37% | 19.68% | 21.13% | 22.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.89% | 30.37% | 19.68% | 21.13% | 22.03% |
| Cost of Revenue | 163.91% | 335.45% | 672.54% | 2,642.30% | -- |
| Gross Profit | 21.60% | 26.13% | 15.70% | 17.59% | 19.21% |
| SG&A Expenses | 10.80% | 16.98% | 9.77% | 18.13% | 24.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.02% | 30.01% | 26.84% | 36.13% | 39.40% |
| Operating Income | 30.98% | 31.14% | 7.22% | -2.03% | -3.46% |
| Income Before Tax | 27.83% | 61.24% | 26.55% | 35.13% | 12.60% |
| Income Tax Expenses | -21.71% | 3.05% | 79.55% | 77.41% | 20.96% |
| Earnings from Continuing Operations | 42.52% | 78.41% | 13.27% | 24.52% | 10.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.52% | 78.41% | 13.27% | 24.52% | 10.33% |
| EBIT | 30.98% | 31.14% | 7.22% | -2.03% | -3.46% |
| EBITDA | 31.51% | 31.81% | 7.57% | -1.63% | -3.34% |
| EPS Basic | 56.92% | 56.21% | -12.63% | -0.51% | -12.30% |
| Normalized Basic EPS | 46.39% | 46.75% | -0.34% | 6.68% | -17.74% |
| EPS Diluted | 57.04% | 56.30% | -12.50% | -0.40% | -12.32% |
| Normalized Diluted EPS | 46.53% | 46.88% | -0.19% | 6.81% | -17.76% |
| Average Basic Shares Outstanding | -2.03% | 144.90% | 145.64% | 146.35% | 146.42% |
| Average Diluted Shares Outstanding | -2.32% | 144.50% | 145.21% | 145.92% | 146.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |